Shord SS - Search Results

1

Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer.

Shord SS, Faucette SR, Gillenwater HH, Pescatore SL, Hawke RL, Socinski MA, Lindley C. Shord SS, et al. Cancer Chemother Pharmacol. 2003 Apr;51(4):328-36. doi: 10.1007/s00280-002-0560-1. Epub 2003 Mar 13. Cancer Chemother Pharmacol. 2003. PMID: 12721761 Clinical Trial.

2

A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.

Gillenwater HH, McCune JS, Lindley C, Faucette S, Shord S, Donahue A, Socinski MA, Stewart CF, Zamboni WC, Kirstein MN, Moore D. Gillenwater HH, et al. Cancer Invest. 2005;23(6):511-9. doi: 10.1080/07357900500201400. Cancer Invest. 2005. PMID: 16203659 Clinical Trial.

3

Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy.

Lindley C, Shea T, McCune J, Shord S, Decker J, Harvey D, Petros WP, Garbriel D, Serody J, Kirby S, Wiley J. Lindley C, et al. Anticancer Drugs. 2004 Jun;15(5):453-9. doi: 10.1097/01.cad.0000127145.50172.51. Anticancer Drugs. 2004. PMID: 15166618 Clinical Trial.

4

Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.

Lindley C, Goodin S, McCune J, Kane M, Amamoo MA, Shord S, Pham T, Yowell S, Laliberte K, Schell M, Bernard S, Socinski MA. Lindley C, et al. Am J Clin Oncol. 2005 Jun;28(3):270-6. doi: 10.1097/01.coc.0000145983.35929.2a. Am J Clin Oncol. 2005. PMID: 15923800 Clinical Trial.

5

Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity.

Shord SS, Bernard SA, Lindley C, Blodgett A, Mehta V, Churchel MA, Poole M, Pescatore SL, Luo FR, Chaney SG. Shord SS, et al. Anticancer Res. 2002 Jul-Aug;22(4):2301-9. Anticancer Res. 2002. PMID: 12174918 Clinical Trial.

6

Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation.

Faucette SR, Hawke RL, Shord SS, Lecluyse EL, Lindley CM. Faucette SR, et al. Among authors: shord ss. Drug Metab Dispos. 2001 Aug;29(8):1123-9. Drug Metab Dispos. 2001. PMID: 11454731

7

The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes.

Lindley C, Hamilton G, McCune JS, Faucette S, Shord SS, Hawke RL, Wang H, Gilbert D, Jolley S, Yan B, LeCluyse EL. Lindley C, et al. Among authors: shord ss. Drug Metab Dispos. 2002 Jul;30(7):814-22. doi: 10.1124/dmd.30.7.814. Drug Metab Dispos. 2002. PMID: 12065440

8

Coagulation products and their uses.

Shord SS, Lindley CM. Shord SS, et al. Am J Health Syst Pharm. 2000 Aug 1;57(15):1403-17; quiz 1418-20. Am J Health Syst Pharm. 2000. PMID: 10938981 Review.

9

Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.

Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, Lindley CM. Faucette SR, et al. Among authors: shord ss. Drug Metab Dispos. 2000 Oct;28(10):1222-30. Drug Metab Dispos. 2000. PMID: 10997944

10

Randomized double-blind study of the Reliefband as an adjunct to standard antiemetics in patients receiving moderately-high to highly emetogenic chemotherapy.

Treish I, Shord S, Valgus J, Harvey D, Nagy J, Stegal J, Lindley C. Treish I, et al. Support Care Cancer. 2003 Aug;11(8):516-21. doi: 10.1007/s00520-003-0467-3. Epub 2003 Jun 27. Support Care Cancer. 2003. PMID: 12836088 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

56 results

Search Page